NCT00198159View on ClinicalTrials.gov

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

February 28, 2006

Study Completion Date

March 31, 2006

Conditions
Refractory Germ Cell Tumors Expressing EGRF
Interventions
DRUG

ZD1839 Iressa

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Indiana University School of Medicine

OTHER